-

Asahi Kasei’s Capacity Expansion for Water Electrolysis and Chlor‑Alkali Equipment in Kawasaki Awarded Regional Economic Incentives

TOKYO--(BUSINESS WIRE)--Asahi Kasei’s project to build new facilities for both alkaline water electrolysis and ion-exchange membrane process chlor-alkali electrolysis equipment has been awarded key regional economic incentives. The incentives include financial support from Kanagawa Prefecture and the City of Kawasaki for the facilities being built in Kawasaki, Japan. For Asahi Kasei, a diversified global company, this represents a significant milestone in accelerating its strategic portfolio transformation.

Asahi Kasei is a comprehensive manufacturer and supplier of alkaline water electrolyzers for hydrogen production. The company is building new facilities for both cell frames and membranes for electrolysis at its plant site in Kawasaki, Kanagawa Prefecture, Japan, targeting a manufacturing capacity of at least 2 GW each by 2028. Together with its current capacity for ion-exchange membrane process chlor-alkali electrolysis equipment, this expansion will raise the company’s total annual capacity for cell frames and membranes to more than 3 GW.

In December 2024, Asahi Kasei’s expansion proposal was selected for governmental support, reflecting expectations for strengthening industrial competitiveness and regional economic development, including in hydrogen-related markets. In October 2025, Asahi Kasei formally approved plans to construct new production facilities and has since been advancing preparations. This will help strengthen the global clean hydrogen supply base while raising Japan's industrial competitiveness in the field of hydrogen.

Positioning its manufacturing site in Kawasaki as a key global hub for both water electrolysis and chlor-alkali systems, Asahi Kasei is concentrating resources there to establish a flexible, resilient supply platform. Backed by the various support initiatives, the company will further expand capacity while contributing to regional economic development.

Looking ahead, Asahi Kasei has stated it will strengthen its technology base and supply capabilities in water electrolysis, while leveraging the complementary strengths of its hydrogen and chlor-alkali operations to build on its global competitiveness.

About Asahi Kasei
Asahi Kasei is a diversified global company that contributes to life and living for people around the world. Since its foundation in 1922, with businesses in ammonia and cellulose fiber, Asahi Kasei has consistently grown through proactive portfolio transformation to meet the evolving needs of every age. With 50,000 employees worldwide, the company contributes to sustainability by providing solutions to the world’s challenges across its three business sectors: Healthcare, Homes, and Material. For more information, visit https://www.asahi-kasei.com/.

Contacts

Asahi Kasei America Inc.
Christian OKeefe
christian.okeefe@ak-america.com

Asahi Kasei Europe GmbH
Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu

Asahi Kasei

TOKYO:3407

Release Summary
Asahi Kasei’s project to build new facilities for electrolysis equipment has been awarded key regional economic incentives.
Release Versions

Contacts

Asahi Kasei America Inc.
Christian OKeefe
christian.okeefe@ak-america.com

Asahi Kasei Europe GmbH
Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu

Social Media Profiles
More News From Asahi Kasei

Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults

TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics, Inc., the global specialty pharmaceutical business of Tokyo-based Asahi Kasei, with U.S. and European business headquarters in Cary, North Carolina, today announced that the U.S. Food and Drug Administration (FDA) has approved HOVILPRI® (pritelivir) 100 mg tablets for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacy...

Asahi Kasei Microdevices Holds IEEE Milestone Commemoration Ceremony in Nobeoka for the Commercialization of Thin-Film Hall Elements

TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices held a ceremony to celebrate the recognition of the 1983 commercialization of thin-film Hall elements as an IEEE Milestone....

Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients

TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics announced that the first patient has been dosed in a randomized Phase 2a clinical trial (NCT07503561) evaluating AIC468....
Back to Newsroom